Initial and programmed combination therapy with oral drugs for severe idiopathic pulmonary arterial hypertension.
A 49-year-old woman suffering from rapidly progressing right-sided heart failure assessed as World Health Organization functional class (WHO-FC) IV is described. After treatment with oxygen and diuretics, she was in WHO-FC III on admission to our hospital, as confirmed by her poor exercise tolerance in cardiopulmonary exercise testing. Upon detailed examination, she was diagnosed as having idiopathic pulmonary arterial hypertension (IPAH). Right heart catheterization (RHC) revealed severe pulmonary hypertension (mPAP = 65 mmHg) with a markedly decreased cardiac index (CI = 1.0 L/minute/m(2)), and an acute vasoreactivity test with nitric oxide inhalation did not show any response. Due to her severe condition, we decided to attempt oral combination therapy consisting of bosentan, tadalafil, and beraprost, prescribed in the same order and titrated up to their maximum respective doses, instead of intravenous (IV) epoprostenol therapy. Her clinical symptoms improved day by day, and the hemodynamic parameters recovered to nearly normal ranges about 6 months after initiation of the combination therapy. Initial/programmed oral combination therapy for severe IPAH patients is not yet fully established, and there is less evidence concerning its efficacy than IV epoprostenol therapy. However, it has tremendous advantages for PAH patients when they respond well. It is very important to further identify what types of PAH patients will respond to this oral combination therapy and should be treated with it as the first-line therapy.
Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Hisataka
H
Maki
Atsushi
A
Yao
Toshiro
T
Inaba
Taro
T
Shiga
Masaru
M
Hatano
Koichiro
K
Kinugawa
Takeshi
T
Yamashita
Tadanori
T
Aizawa
Ryozo
R
Nagai
D000284:Administration, Oral; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D000077300:Bosentan; D002243:Carbolines / Q000008:administration & dosage*; D002302:Cardiac Output / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D004452:Echocardiography / Q000187:drug effects; D004562:Electrocardiography / Q000187:drug effects; D011464:Epoprostenol / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D005260:Female; D006333:Heart Failure / Q000175:diagnosis / Q000188:drug therapy*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006976:Hypertension, Pulmonary / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D007262:Infusions, Intravenous; D008875:Middle Aged; D013449:Sulfonamides / Q000008:administration & dosage*; D000068581:Tadalafil; D014665:Vasodilator Agents / Q000008:administration & dosage*
D000959:Antihypertensive Agents; D002243:Carbolines; D013449:Sulfonamides; D014665:Vasodilator Agents; C048081:beraprost; D000068581:Tadalafil; D011464:Epoprostenol; D000077300:Bosentan